KPP
PFE icon

Kings Path Partners’s Pfizer PFE Stock Holding History

Kings Path Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.6K Hold
2,850
– – 0.02% 164
2026
Q1 		$71K Hold
2,850
– – 0.02% 152
2025
Q4 		$71K Sell
2,850
-100
-3% -$2.52K 0.02% 152
2025
Q3 		$75.2K Buy
2,950
+100
+4% +$2.47K 0.03% 144
2025
Q2 		$69.1K Hold
2,850
– – 0.03% 143
2025
Q1 		$72.2K Hold
2,850
– – 0.04% 132
2024
Q4 		$75.6K Hold
2,850
– – 0.03% 158
2024
Q3 		$82.5K Hold
2,850
– – 0.03% 150
2024
Q2 		$79.7K Buy
+2,850
New +$78.5K 0.04% 139

Other funds holding PFE

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
ORIO
Old Republic International (ORI) Chicago, Illinois $2.67B AUM 26.94% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
KC
Kepler Cheuvreux Nyon $1.75B AUM 37.37% 1-Year Est. Return

Kings Path Partners's PFE Position: Q2 2026 in Review

Kings Path Partners held its Pfizer (PFE) position steady in Q2 2026 at 2,850 shares worth $68.6K. The position accounts for 0.02% of the portfolio, ranked #164.

Kings Path Partners first reported a position in PFE in Q2 2024 and has held it in 9 quarters since. The position peaked at $82.5K in Q3 2024. 631 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Kings Path Partners held 2,850 shares of Pfizer worth $68.6K as of Q2 2026.
  • Kings Path Partners left its Pfizer share count unchanged in Q2 2026.
  • Pfizer made up 0.02% of Kings Path Partners's portfolio in Q2 2026, its #164 holding.
  • Kings Path Partners first reported a position in Pfizer in Q2 2024 and has held it in 9 quarters since.
  • Kings Path Partners's Pfizer position peaked at $82.5K in Q3 2024.
  • 631 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Kings Path Partners's 13F filing for Q2 2026, filed 14 Jul 2026.